CliffBio
small molecule

FAMCICLOVIR

FAMCICLOVIR

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameFAMCICLOVIR
Active ingredientFAMCICLOVIR
Strength125MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2011
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FAMCICLOVIR patent cliff — loss of exclusivity — | CliffBio